DDrare: Database of Drug Development for Rare Diseases

206. 脆弱X症候群
［臨床試験数：98，薬物数：73（DrugBank：27），標的遺伝子数：46，標的パスウェイ数：57］

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-flumazenil; 18F-FTC-146; ACIDUM ASCORBICUM D6; AF056; AFQ056; AZD7325; AZD7325 (High-Dose); AZD7325 (Low-Dose); Acamprosate; Acetate; Acidum ascorbicum; Alpha-tocopherol; Ampalex; Arbaclofen; Aripiprazole; Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E); Ascorbic acid; BPN14770; CBD; CCD 1042, MD 9150000, Mepalon 1042, SPT316; CX516; CX516 (Ampalex®); Donepezil; EGCG; EGCG FontUp; Flumazenil; Fluoxetin; GANAXOLONE; Gaboxadol; Ganaxolone; Lovastatin; Lovastatin, then Minocycline/Lovastatin; MG01CI extended-release tablet; MGlu5 antagonist; Mavoglurant; Metformin; Methylphenidate; Methylphenidate, fluoxetin, risperidone; Minocycline; Minocycline hydrochloride; Minocycline, then Minocycline/Lovastatin; NNZ-2566; NPL-2009; OV101; OV101 (gaboxadol); Other: Biological samples; Other: Cognitive training; Other: Language Intervention; Other: MRI; Oxytocin; Oxytocin 24IU; Oxytocin 48IU; RO4917523; RO4917523 0.5 mg; RO4917523 1.5 mg; Riluzole; Risperidone; Ro 491-7523/F18; Ro 491-7523/F19; STX107; STX209; Sertraline; Sugar pill; TOCOPHERYL ACETATE; Tocopherol; Tocopheryl acetate; Vitamin C; Vitamin C 10mg/Kg Vitamin E 10 mg/Kg; Vitamin E; ZYN002 - CBD Transdermal Gel; [18F]FPEB; [18F]FPEB PET imaging; [18F]flumazenil

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03624556 (ClinicalTrials.gov)	January 29, 2018	6/6/2018	Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)	Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)	Down Syndrome;Fragile X Syndrome	Dietary Supplement: EGCG FontUp;Other: Placebo FontUp	Parc de Salut Mar	Hospital Infantil Universitario Niño Jesús, Madrid, Spain;Instituto Hispalense de Pediatría, Sevilla, Spain;Hospital Universitario Marqués de Valdecilla;Institut Jerome Lejeune	Active, not recruiting	6 Years	12 Years	All	70	N/A	Spain
2	NCT01855971 (ClinicalTrials.gov)	June 11, 2013	9/5/2013	Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome (TESFX)	Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)	Fragile X Syndrome	Dietary Supplement: EGCG;Dietary Supplement: Placebo;Other: Cognitive training	Parc de Salut Mar	NULL	Completed	18 Years	60 Years	All	44	Phase 2	Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03624556
(ClinicalTrials.gov)

January 29, 2018

6/6/2018

Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)

Down Syndrome;Fragile X Syndrome

Dietary Supplement: EGCG FontUp;Other: Placebo FontUp

Parc de Salut Mar

Hospital Infantil Universitario Niño Jesús, Madrid, Spain;Instituto Hispalense de Pediatría, Sevilla, Spain;Hospital Universitario Marqués de Valdecilla;Institut Jerome Lejeune

Active, not recruiting

6 Years

12 Years

All

N/A

Spain

NCT01855971
(ClinicalTrials.gov)

June 11, 2013

9/5/2013

Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome (TESFX)

Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)

Fragile X Syndrome

Dietary Supplement: EGCG;Dietary Supplement: Placebo;Other: Cognitive training

Parc de Salut Mar

NULL

Completed

18 Years

60 Years

All

Phase 2

Spain